Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT00731198 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

650

Enrollment

OTHER

Sponsor class

Conditions

ERCP
Pancreatic Diseases
Bile Duct Diseases

Interventions

DRUG: Drotaverine hydrochloride
DRUG: Hyoscine-N-butylbromide

Sponsor

Changhai Hospital